Integrins as Drug Targets in Vascular and Related Diseases

Abstract

Review Integrins as Drug Targets in Vascular and Related Diseases Emily Meredith 1,*, and Martin A. Schwartz 1,2,3 1  Yale Cardiovascular Research Center, Department of Internal Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511, USA, martin.schwartz@yale.edu 2  Department of Cell Biology, Yale School of Medicine, New Haven, CT 06520, USA. 3  Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA. * Correspondence: Emily.meredith@yale.edu Received: 6 April 2024; Revised: 28 May 2024; Accepted: 29 May 2024; Published: 21 June 2024 Abstract: Integrins are transmembrane receptors that, as critical participants in a vast range of pathological processes, are potential therapeutic targets. However, in only a few cases has the promise been realized by drug approval. In this review, we briefly review basic integrin biology and participation in disease, challenges in the development of safe, effective integrin-targeted therapies, and recent advances that may lead to progress.